SLC5A2 and prostate carcinoma: The first is to lend support for the conduct of a RCT of SGLT2 inhibitors, given both the evidence from Zhang of their effectiveness and that the cost-effectiveness conclusions we present depend on the price at which SGLT2 inhibitors would be offered for a novel prostate cancer indication.